The protective effects of allopurinol against IL-17A-induced inflammatory response in mast cells

Zhang, Zhaozhen; Ma, Xiaoran; Zha, Zhuqing; Zhao, Zhigang; Li, Jitian

doi:10.1016/j.molimm.2021.10.020

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, several drugs not previously used for the treatment of RA have also been found to have therapeutic effects on the condition, and the pharmacological mechanisms of these drugs have also been explored. Allopurinol, a classic inhibitor of uric acid production, can significantly inhibit the NF-κB pathways and achieve RA therapeutic effects by regulating the activated iNOS/NO axes [71]. Antianginal drug Nicodil was also proven to have a protective effect for RA by correcting iNOS and eNOS levels in vitro model [72].…”

Section: Conventional Dmardsmentioning

confidence: 99%

Nitric Oxide Synthases in Rheumatoid Arthritis

et al. 2023

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease characterized by severe joint damage and disability. However, the specific mechanism of RA has not been thoroughly clarified over the past decade. Nitric oxide (NO), a kind of gas messenger molecule with many molecular targets, is demonstrated to have significant roles in histopathology and homeostasis. Three nitric oxide synthases (NOS) are related to producing NO and regulating the generation of NO. Based on the latest studies, NOS/NO signaling pathways play a key role in the pathogenesis of RA. Overproduction of NO can induce the generation and release of inflammatory cytokines and act as free radical gas to accumulate and trigger oxidative stress, which can involve in the pathogenesis of RA. Therefore, targeting NOS and its upstream and downstream signaling pathways may be an effective approach to managing RA. This review clearly summarizes the NOS/NO signaling pathway, the pathological changes of RA, the involvement of NOS/NO in RA pathogenesis and the conventional and novel drugs based on NOS/NO signaling pathways that are still in clinical trials and have good therapeutic potential in recent years, with an aim to provide a theoretical basis for further exploration of the role of NOS/NO in the pathogenesis, prevention and treatment of RA.

show abstract

Section: Conventional Dmardsmentioning

confidence: 99%